Palmitoyl Pentapeptide-4 vs Matrixyl 3000: Buyer Comparison

The names describe different materials

Palmitoyl Pentapeptide-4 is a single INCI peptide commonly linked with the original Matrixyl history. Matrixyl 3000 is associated with a two-peptide system containing Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. They are not synonyms and should not share one undifferentiated specification.

Start with grade identity

Ask whether the material is an original branded grade, an INCI-equivalent ingredient or a custom blend. Record manufacturer, product code, complete composition and authorized trade-name use. A generic quotation that says only “Matrixyl” is not specific enough for purchasing.

Compare active basis

Both materials may be sold as dilute stock solutions. Addition percentage therefore cannot be compared without knowing the actual peptide content and carrier system. Calculate cost per unit of defined active and the effect of carriers on the finished formula.

Evidence

Palmitoyl Pentapeptide-4 has published controlled human research in a moisturizer vehicle. Matrixyl 3000-type systems have separate supplier and finished-product evidence. A study on one does not substantiate the other, and neither automatically proves performance of a new serum.

Formula strategy

Choose Palmitoyl Pentapeptide-4 for a focused single-peptide story or a Matrixyl 3000-type grade for a documented two-peptide concept. A formula may include both, but only when the added complexity, cost and claim plan are justified.

Processing and stability

Confirm carrier, pH, temperature, preservation and storage. Add according to supplier guidance and evaluate the complete formula for pH drift, haze, viscosity, odor, microbiology and package interaction.

Decision checklist

Compare identity, evidence relevance, active basis, cost-in-use, carrier load, formulation support, MOQ, lead time and batch documentation. Lock the chosen grade before pilot and label approval.

Selected research for further reading

These sources provide background and do not substitute for finished-product substantiation.

• Palmitoyl pentapeptide clinical study